1. Digitum: Repositorio Institucional de la Universidad de Murcia
  2. Revistas y Congresos
  3. EditUM Revistas
  4. Histology and histopathology
  5. Vol.37, nº5 (2022)
Por favor, use este identificador para citar o enlazar este ítem: https://doi.org/10.14670/HH-18-421

Registro completo de metadatos
Campo DCValorLengua/Idioma
dc.contributor.authorMaher, Mustafa A.-
dc.contributor.authorKandeel, Wafaa A.-
dc.contributor.authorHammam, Olfat A.-
dc.contributor.authorAttia, Yasmeen M.-
dc.contributor.authorMahmoud, Soheir-
dc.contributor.authorSalah, Mohamed-
dc.date.accessioned2023-02-17T08:24:52Z-
dc.date.available2023-02-17T08:24:52Z-
dc.date.issued2022-
dc.identifier.citationHistology and Histopathology Vol. 37, nº5 (2022)es
dc.identifier.issn0213-3911-
dc.identifier.issn1699-5848-
dc.identifier.urihttp://hdl.handle.net/10201/128544-
dc.description.abstractThe combination of insulin and DMSO is a patented (Publication No US8987199B2), noninvasive, pharmaceutically strategized preparation for direct noseto-brain delivery (DN2BD) suggested for the treatment of Alzheimer’s disease (AD). Although its main ingredients have been individually researched, no histopathological investigations have been conducted to address this combination effect on the CNS and nasal tissues in animals. The present work was, therefore, designed to investigate the potential histopathological changes induced by this new pharmaceutical combination using a newly developed refractory staining method. The findings presented herein showed no signs of treatment-related lesions or behavioral changes in Sprague Dawley rats following a three-month successive treatment with two strengths of the formula.es
dc.formatapplication/pdfes
dc.format.extent9es
dc.languageenges
dc.publisherUniversidad de Murcia, Departamento de Biologia Celular e Histiologiaes
dc.relationSin financiación externa a la Universidaes
dc.rightsinfo:eu-repo/semantics/openAccesses
dc.rightsAttribution-NonCommercial-NoDerivatives 4.0 Internacional*
dc.rights.urihttp://creativecommons.org/licenses/by-nc-nd/4.0/*
dc.subjectHistopathologyes
dc.subjectInsulines
dc.subjectDMSOes
dc.subjectAlzheimer’s diseasees
dc.subjectNose-to-brain drug deliveryes
dc.subjectFluoresceine Sodiumes
dc.subject.otherCDU::6 - Ciencias aplicadas::61 - Medicina::616 - Patología. Medicina clínica. Oncologíaes
dc.titleHistopathological evaluation of insulin-DMSO formula designed for direct nose-to-brain deliveryes
dc.typeinfo:eu-repo/semantics/articlees
dc.identifier.doihttps://doi.org/10.14670/HH-18-421-
Aparece en las colecciones:Vol.37, nº5 (2022)

Ficheros en este ítem:
Fichero Descripción TamañoFormato 
Maher-37-431-439-2022.pdf7,5 MBAdobe PDFVista previa
Visualizar/Abrir
Mostrar el registro sencillo del ítem Mostrar el registro PREMIS del ítem  Estadísticas


Este ítem está sujeto a una licencia Creative Commons Licencia Creative Commons Creative Commons